Adjuvant therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib for 12 months led to long-term relapse-free survival (RFS) with no apparent long-term toxicities in patients with resected stage III melanoma with BRAF V600E or V600K mutations, according to the extended follow-up results of the phase III COMBI-AD* trial.
COVID-19 patients carry particularly high viral loads during the early stages of the disease, with millions of virus exhaled in their breath per hour, reveals a study — which indicates that breath emission could possibly contribute to airborne transmission of the virus.
A 4-week delay in cancer treatment can increase mortality across surgical, systemic treatment, and radiotherapy indications for seven cancers, with longer delays being more and more harmful to patients, suggest the results of a systematic review and meta-analysis.
Giving crushed prasugrel to patients with ST-segment elevation myocardial infarction (STEMI) en route to the hospital for planned PCI* does not improve reperfusion rates compared with giving the tablets whole in the COMPARE CRUSH trial.
Meteorological factors, such as humidity, precipitation, ambient temperature, and wind speed, seem to affect the transmissibility of the respiratory syncytial virus (RSV), according to a recent Singapore study.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.